James Byrne, VP Site for Ipsen Manufacturing Ireland, discusses the strategic importance of the Ireland site as the sole provider of peptides for products generating over 50 percent of Ipsen’s global revenues; his strategy for attracting and retaining the best talent; and his thoughts on the impact of new manufacturing trends on Ipsen Manufacturing Ireland.
Can you provide an overview of the strategic significance of this manufacturing facility for Ipsen’s global operations?
This is one of Ipsen’s key manufacturing facilities globally. Sales from these two products amounted to over EUR 700 million in 2015, which is over half of Ipsen’s global revenues of EUR 1.4 billion in 2015.
